Insider at CymaBay Therapeutics (CBAY) Makes Significant Sale of Stock

Monday, February 05, 2018 10:15 PM ET

Insider at CymaBay Therapeutics (CBAY) Makes Significant Sale of Stock

There was a notable sale of shares of CymaBay Therapeutics by an insider today, as indicated in a form 4 document filed with the SEC. One insider — Kurt von Emster, Director — sold 90,098 shares in the company having a market value of approximately $1,094,611. There was one insider buy/sell transaction in the past 90 days prior to this transaction which resulted in the sale of 647,086 shares. Adding the most recent activity to this 90-day history indicates insider trades have been net sales of 737,184 shares and have averaged 368,592 shares per transaction over this time period.

Insider buy/sell trading at CymaBay Therapeutics is higher than the 280 peer company average over the last 90-day period. The Bio Therapeutic Drugs peer group saw 325 buy/sell trades during this period for an average of 1.2 transactions per company. The number of shares per buy/sell trade for CymaBay Therapeutics insiders was also higher. Within the peer group there were 33,507,513 shares purchased and 43,306,103 shares sold with company insiders selling 30,150 shares on average.

Insider buying and selling activity that is significant has been determined by eliminating all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers in evaluating and writing this story.

Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at Copyright 2018 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.